Ronald de Wit, MD; Piet J.M. Bakker, MD; Kees H.N. Veenhof, PhD; Sven A. Danner, PhD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: Kovacs and colleagues (1) recently reported on combined treatment with interferon-alpha and zidovudine in patients with the acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma. In their discussion, the question was raised whether the interferon-alpha alone or the combination was responsible for the antitumor activity. As we have shown in our previous single-agent interferon-alpha study (2), all major responses that were induced by the initial daily interferon-alpha schedule further improved or became complete responses during the thrice weekly maintenance schedule. Because Kovacs and colleagues escalated interferon-alpha towards high-dose during the initial 2 weeks as well, they may have induced
de Wit R, Bakker PJ, Veenhof KH, et al. Continued Zidovudine and Interferon-Alpha Therapy in Kaposi Sarcoma and the Acquired Immunodeficiency Syndrome (AIDS). Ann Intern Med. 1990;112:306–307. doi: https://doi.org/10.7326/0003-4819-112-4-306
Download citation file:
Published: Ann Intern Med. 1990;112(4):306-307.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use